# The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
Canonical URL: https://biopharmsignal.com/news/RNA/the-new-england-journal-of-medicine-publishes-results-from-phase-1-2-marinar-trial-of-delpacibart-etedesiran-del-desiran-for-treatment-of-myotonic-dystrophy-type-1
Ticker: RNA
Company: Avidity Biosciences
Source: Avidity Biosciences
Published: 2026-02-18 22:00 EST
Original Source URL: https://investors.aviditybiosciences.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-02-27 14:16 EST — [Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy](https://biopharmsignal.com/news/RNA/novartis-successfully-completes-acquisition-of-avidity-biosciences-strengthening-late-stage-neuroscience-pipeline-and-advancing-xrna-strategy) — Source: Avidity Biosciences
- 2026-02-26 21:02 EST — [Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference](https://biopharmsignal.com/news/RNA/avidity-biosciences-announces-multiple-upcoming-presentations-at-2026-muscular-dystrophy-association-mda-clinical-and-scientific-conference) — Source: Avidity Biosciences
- 2026-02-23 13:00 EST — [Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders](https://biopharmsignal.com/news/RNA/avidity-biosciences-announces-intention-to-adjourn-and-reconvene-special-meeting-of-stockholders) — Source: Avidity Biosciences
- 2026-02-18 22:00 EST — [The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1](https://biopharmsignal.com/news/RNA/the-new-england-journal-of-medicine-publishes-results-from-phase-1-2-marinar-trial-of-delpacibart-etedesiran-del-desiran-for-treatment-of-myotonic-dystrophy-type-1) — Source: Avidity Biosciences
- 2026-02-03 02:44 EST — [Avidity Biosciences Announces Expected Record Date for Spin-Off](https://biopharmsignal.com/news/RNA/avidity-biosciences-announces-expected-record-date-for-spin-off) — Source: Avidity Biosciences
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)